The Combination of Anti-CTLA-4 and PD1–/– Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Our laboratory recently reported what we believe is the first valid animal model of idiosyncratic drug-induced liver injury (IDILI) by treating PD1-/- mice with an anti-CTLA-4 antibody and amodiaquine (AQ). PD1 and CTLA-4 are important immune checkpoint receptors that are involved in inducing immune tolerance. This model was able to produce significant liver injury that looks very similar to the liver injury seen in humans. Although this model was shown to work with AQ, the question becomes whether blocking immune tolerance would unmask the potential of other drugs to cause IDILI. In this study, we tested isoniazid and nevirapine, both drugs with significant histories of causing IDILI in humans even though they do not cause significant injury in animals with doses that result in therapeutic blood levels. Both drugs in combination with these immune checkpoint inhibitors caused mild but significant delayed onset liver injury, which is similar to the mild injury that they can cause in humans. INH-induced liver injury in this model was associated with an increase in NK cells, while NVP-induced liver injury was associated with a greater increase in CD8 T cells. Although the liver injury caused by these drugs in this model was mild, these results suggest that impairing immune tolerance may be a general method for unmasking the potential of drugs to cause IDILI and therefore provide a screening tool for drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chakraborty, M., Fullerton, A. M., Semple, K., Chea, L. S., Proctor, W. R., Bourdi, M., Kleiner, D. E., Zeng, X., Ryan, P. M., Dagur, P. K., et al. (2015) · Hepatology · doi:10.1002/hep.27764 · Cited by 64
Cited by
Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management
Mosedale, M., & Watkins, P. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.564 · Cited by 203
Suzman, D. L., Pelosof, L., Rosenberg, A., & Avigan, M. I. (2018) · Liver International · doi:10.1111/liv.13746 · Cited by 189
Mechanisms of immune checkpoint inhibitor-mediated liver injury
Shojaie, L., Ali, M., Iorga, A., & Dara, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.003 · Cited by 98
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Mechanism of Idiosyncratic Drug Induced Liver Injury (DILI): Unresolved Basic Issues
Teschke, R., & Uetrecht, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-2020-ubih-05 · Cited by 58
Self-citationMechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49
Self-citationWhat have we learned from animal models of idiosyncratic, drug-induced liver injury?
Roth, R. A., & Ganey, P. E. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1760246 · Cited by 8
Metadata
- Authors
- Mak, A., & Uetrecht, J.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-11-20
- Volume
- 28
- Issue
- 12
- Pages
- 2287-2291
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2341426049
- Cited by
- 76
- References
- 1
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.